Landscape Capital Management L.L.C. Purchases Shares of 6,279 IDEXX Laboratories, Inc. $IDXX

Landscape Capital Management L.L.C. acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 6,279 shares of the company’s stock, valued at approximately $4,248,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Virtus Advisers LLC purchased a new position in IDEXX Laboratories during the 3rd quarter worth approximately $26,000. Park Place Capital Corp purchased a new position in shares of IDEXX Laboratories during the 4th quarter valued at $29,000. Mowery & Schoenfeld Wealth Management LLC grew its holdings in shares of IDEXX Laboratories by 58.8% during the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after acquiring an additional 20 shares in the last quarter. Wormser Freres Gestion grew its holdings in shares of IDEXX Laboratories by 671.4% during the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after acquiring an additional 47 shares in the last quarter. Finally, WealthCollab LLC purchased a new position in shares of IDEXX Laboratories during the 2nd quarter valued at $30,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on IDXX shares. Citigroup started coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target on the stock. Wall Street Zen upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday. UBS Group lowered their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Finally, Stifel Nicolaus lowered their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Stock Up 0.5%

IDEXX Laboratories stock opened at $560.88 on Friday. The firm has a market cap of $44.24 billion, a price-to-earnings ratio of 41.30, a P/E/G ratio of 3.07 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. IDEXX Laboratories, Inc. has a fifty-two week low of $506.91 and a fifty-two week high of $769.98. The firm has a fifty day moving average price of $563.06 and a two-hundred day moving average price of $627.69.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business’s revenue was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.